Data from the JAK-pot collaboration of registries show that cycling JAKinibs and switching to a bDMARD appear to have similar effectiveness, after failing the first JAKinib.

With the arrival of new JAKinibs with different JAK inhibition profiles, there is the possibility of using another JAKinib after an inadequate response to the first, in patients with RA, yet there are no data on the effectiveness of using a JAKinib compared with a bDMARD in patients with first JAKinib treatment failure.

As such, Pombo-Suarez, et al. used data from the JAK-pot collaboration to compare the efficacy of a second JAKinib versus a bDMARD, after failure of the first JAKinib, and examine response and reason for stopping second-line therapies.